Table 2.
Summarized results reported from published studies with or without detection of the HCMV in clinical samples obtained from GBM patients using IF, IHC, ISH, PCR, ELISA, NGS and FACS methods.
| Methods | Tumor Tissue Specimens | Blood Samples | ||||||
|---|---|---|---|---|---|---|---|---|
| IF | IHC | ISH | PCR | NGS | FACS | PCR | ELISA | |
| (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | |
| Articles | 4/4 | 25/39 | 10/15 | 29/48 | 0/7 | 6/6 | 8/15 | 14/20 |
| (100) | (64.1) | (66.7) | (60.4) | 0 | (100) | (53.3) | (70.0) | |
| Analyses | 6/6 | 51/74 | 11/18 | 73/85 | 0/7 | 8/8 | 14/20 | 28/29 |
| (100) | (68.9) | (61.1) | (85.9) | 0 | (100) | −70 | (96.6) | |
| Positive | 119/217 | 1500/3111 | 132/339 | 778/2676 | 0/681 | 216/288 | 238/883 | 640/1249 |
| Samples | (54.8) | (48.2) | (38.9) | (29.1) | 0 | (75.0) | (27.0) | (51.2) |
| Analyzed | 217/7024 | 3111/7024 | 339/7024 | 2676/7024 | 681/7024 | 288/2420 | 883/2420 | 1249/2420 |
| Samples/ | (3.1) | (44.3) | (4.8) | (38.1) | (9.7) | (11.9) | (36.5) | (51.6) |
| Total number of samples | ||||||||
ISH: in situ hybridization; PCR: polymerase chain reaction; NGS: next-generation sequencing; IF: immunofluorescence; IHC: immunohistochemical staining; FACS: flow cytometry analysis.